Yuge Neuropsychiatric Hospital, Kumamoto, Japan.
Yatsushiro Kosei Hospital, Kumamoto, Japan.
Neuropsychopharmacol Rep. 2023 Sep;43(3):425-433. doi: 10.1002/npr2.12371. Epub 2023 Aug 10.
We conducted a 1-year retrospective mirror-image study to investigate the effect of aripiprazole once monthly (AOM) on rehospitalization for bipolar disorder.
Participants were recruited from psychiatric emergency and acute care hospitals in western Japan. We included 39 participants with bipolar disorder who had been administered AOM for at least 1 year with no missing medical records during the observational period. The primary outcomes were rehospitalization rate, number of rehospitalizations, total hospitalization days, and time to rehospitalization in the context of overall psychiatric readmissions. The significance level was set at p < 0.05.
AOM significantly reduced the rehospitalization rate from 23/39 (59%) to 7/39 (18%) (p = 0.001). The number of rehospitalizations decreased significantly from a mean of 0.85 per person-year to 0.41 per person-year (p = 0.048). The total hospitalization days significantly decreased from a mean of 34.9 days to 14.4 days (p = 0.008). AOM significantly prolonged the time to rehospitalization (p < 0.001).
This study found that AOM reduces overall psychiatric rehospitalization for bipolar disorder based on data from 1 year before and after AOM administration in the real-world setting. Future studies should examine the robustness and persistence of the rehospitalization preventive effect of AOM with larger sample sizes and longer observation periods beyond 1 year.
我们进行了为期 1 年的回顾性镜像研究,以调查阿立哌唑每月 1 次给药(AOM)对双相情感障碍再住院的影响。
参与者来自日本西部的精神科急诊和急性护理医院。我们纳入了 39 名接受 AOM 治疗至少 1 年且在观察期间无缺失病历的双相情感障碍患者。主要结局是在全 Psychiatry 再入院背景下的再住院率、再住院次数、总住院天数和再住院时间。显著性水平设为 p < 0.05。
AOM 显著降低了再住院率,从 23/39(59%)降至 7/39(18%)(p = 0.001)。再住院次数从人均 0.85 次/人年显著减少至 0.41 次/人年(p = 0.048)。总住院天数从人均 34.9 天显著减少至 14.4 天(p = 0.008)。AOM 显著延长了再住院时间(p < 0.001)。
这项研究发现,基于 AOM 给药前后 1 年的真实世界数据,AOM 可降低双相情感障碍的总体 Psychiatry 再住院率。未来的研究应使用更大的样本量和超过 1 年的更长观察期,进一步检验 AOM 预防再住院效果的稳健性和持久性。